Person:
YILDIZ, PELİN

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
PELİN
Last Name
YILDIZ
Name
Email Address
Birth Date

Filters

2013 - 20142
Reset filters

Settings

Has files: true × Author: GÜCİN, ZÜHAL × Author: TOSUNER, ZEYNEP ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Immunoexpression of TTF-1 in Non-Lung Tumors
    (2014-12-01T00:00:00Z) TOSUNER, ZEYNEP; ARICI, Dilek Sema; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; SÖNMEZ, FATMA CAVİDE; YILDIZ, PELİN; TOSUNER, ZEYNEP; ARICI, DILEK SEMA; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; SÖNMEZ, FATMA CAVİDE; YILDIZ, PELİN
    Objective: Thyroid transcription factor-1 (TTF-1) immunoexpression is frequently determined in small-cell lung carcinomas, as well as primary lung adenocarcinomas. While dealing with metastatic carcinomas, TTF-1 immunoexpression is a significant indicator of primary lung carcinomas. Recent studies have revealed that TTF-1 immunoexpression is also defined in non-lung cancers, such as squamous cell carcinomas of different sites and certain neuroendocrine tumors. The verified data obtained from these studies indicate that a straightforward diagnosis of primary lung carcinoma in cases with positive TTF-1 immunoexpression can cause diagnostic contradictions. The aim of our study is to investigate the immunoexpression status of TTF-1 in common non-lung tumors. Methods: A total of 85 cases that were diagnosed in our institute between the years 2011-2012 were included in our study. After a review of the pathological slides prepared from these tumors [colon adenocarcinoma (n: 15), renal cell carcinoma (n: 15), prostate adenocarcinoma (n: 15), invasive papillary urothelial carcinoma (n: 15), invasive ductal carcinoma of breast (n: 15), and neuroendocrine tumors (n: 10)] TTF-1 immunohistochemistry was applied. Semiquantative evaluation based on the distribution and intensity of the staining was performed by two pathologists, respectively. Results: Positive immunostaining was evident in only 1 case of colon adenocarcinoma out of 85 cases. Conclusion: Our study demonstrated that TTF-1 immunoexpression is a very rare finding (1%) in non-lung tumors. This result provides that anti-TTF-1 is a reliable antibody in the interpretation of primary lung carcinomas. In fact, further studies with a large number of cases are needed to confirm the sensitivity and specificity of TTF-1.
  • Thumbnail Image
    PublicationOpen Access
    Hamartoma of the breast in two patients: A case report
    (2013-08-01T00:00:00Z) Sonmez, FATMA CAVİDE; Gucin, ZÜHAL; Yildiz, PELİN; Tosuner, ZEYNEP; SÖNMEZ, FATMA CAVİDE; GÜCİN, ZÜHAL; YILDIZ, PELİN; TOSUNER, ZEYNEP
    Breast hamartomas are rare, benign, tumor-like nodules composed of glandular, adipose and fibrous tissue. The hamartoma was first described in 1971 as a lipofibroadenoma, fibroadenolipoma or adenolipoma, based on the predominant component of the breast tissue. Clinical findings resemble fibroadenoma and if there is a palpable mass, the patients may receive an immediate diagnosis. Ductal hyperplasia, apocrine metaplasia, calcification and adenosis may occur within the hamartoma, with rarer instances of lobular or ductal intraepithelial neoplasms. Although hamartoma is usually benign, a malignant transformation is possible. An excision and histological examination is necessary for the differential diagnosis and also for any epithelial lesions of the hamartoma. Simple excision is enough for treatment if there is no coincidental epithelial malignant lesion. The patients in the present study were treated by simple excision as there were no proliferative changes in the lesions. No recurrence or other problems were detected in the 18-month follow-up. The current study presents two cases of breast hamartoma that were diagnosed as an adenolipoma and a fibroadenolipoma, and then describes the macroscopic and microscopic observations of these lesions.